Human African trypanosomiasis (sleeping sickness) occurs in sub-Saharan Africa. It is caused by the protozoan parasite Trypanosoma brucei, transmitted by tsetse fl ies. Almost all cases are due to Trypanosoma brucei gambiense, which is indigenous to west and central Africa. Prevalence is strongly dependent on control measures, which are often neglected during periods of political instability, thus leading to resurgence. With fewer than 12 000 cases of this disabling and fatal disease reported per year, trypanosomiasis belongs to the most neglected tropical diseases. The clinical presentation is complex, and diagnosis and treatment diffi cult. The available drugs are old, complicated to administer, and can cause severe adverse reactions. New diagnostic methods and safe and eff ective drugs are urgently needed. Vector control, to reduce the number of fl ies in existing foci, needs to be organised on a pan-African basis. WHO has stated that if national control programmes, international organisations, research institutes, and philanthropic partners engage in concerted action, elimination of this disease might even be possible.
Introduction
Human African trypanosomiasis, which is fatal if left untreated, aff ects rural populations in sub-Saharan Africa. Its prevalence has changed during the past 100 years largely because of control and intervention programmes. After major outbreaks at the beginning of the 19th century, the disease was almost eliminated in the mid-1960s, followed by resurgence in the late 1990s and a fall in the number of cases in recent years. Although the present number of cases (50 000-70 000) seems negligible on a worldwide scale, the characteristics and focal distribution of the disease can have a great socioeconomic eff ect on aff ected villages.
Diagnosis and treatment is unsatisfactory and needs more research and development. As one of the most neglected tropical diseases, African trypanosomiasis could catch the attention of initiatives and public-private partnerships. With new methods to diagnose and treat patients and to control transmission by the tsetse fl y, elimination of the disease might be possible.
Epidemiology
The geographical range of human African trypano somiasis (sleeping sickness) is restricted to sub-Saharan Africa (fi gure 1), where there are suitable habitats for its vector, the tsetse fl y. Together with the animal form of African trypanosomiasis, known as nagana, human disease is a major cause of rural underdevelopment in sub-Saharan Africa. Although the disease has also been reported in urban and periurban areas, 1 it mainly aff ects poor and remote rural regions. Disease transmission occurs in children and adults during activities such as farming, hunting, fi shing, or washing clothes. The African trypanosomes pathogenic for man belong to the species Trypanosoma brucei, which has three subspecies: T b gambiense, which causes endemic disease in central and west Africa; T b rhodesiense, which causes more acute disease in east and southern Africa (fi gure 1); and T b brucei, which usually infects domestic and wild animals but not man. The strict geographical separation between T b gambiense and T b rhodesiense could soon change, however, because the continued spread of T b rhodesiense in Uganda towards the northwest might cause an overlap of the distributions of the two forms of disease.
2 Sporadic reports have appeared of disease in man caused by nonhuman-pathogenic trypanosome species. These species are T b brucei, 3 T congolense, 4 and T evansi.
5
Three major epidemics have ravaged the continent in the past century. 6 The fi rst, which largely aff ected equatorial Africa, took place between 1896 and 1906, and killed an estimated 800 000 people. 7 A second major epidemic between 1920 and the late 1940s prompted the colonial powers to invest in vector control and mobile teams to undertake active surveillance of the population-two strategies that are still the pillars of control. These control mechanisms were initially eff ective, and the disease was almost eradicated in the early 1960s. However, after the advent of independence there was a collapse of surveillance and control activities in most endemic countries, often exacerbated by civil confl icts. This collapse led to a progressive re-emergence of the disease, which reached a peak in the late 1990s in the Democratic Republic of the Congo (DRC), Angola, Central African Republic, southern Sudan, and Uganda (fi gure 2). of all reported cases in 2006, showed no similar decrease because only a few endemic countries implemented control programmes. 18 However, these fi gures should be regarded with caution since under-reporting is known to mask the true burden of T b rhodesiense disease.
19,20 The decrease in reported T b gambiense infections is encouraging, but because African trypanosomiasis mainly aff ects remote rural communities in regions with poor health infrastructures, many cases certainly remain undiagnosed or unreported, and the true burden of disease in Africa remains unknown. WHO used a ratio of 1:3-4 to calculate the fi gure of 50 000-70 000 new cases in 2004. 21 Hidden pockets of highly endemic T b gambiense disease remain, as shown by the high number of patients (n=1800) diagnosed and treated by Médecins Sans Frontières between July, 2007, and June, 2008, in two remote areas of Central African Republic (Batangafo) and DRC (Doruma and Banda) (C F, unpublished data). Similarly, the local burden of T b rhodesiense illness on individuals and health services remains high in some aff ected areas.
22
Human African trypanosomiasis due to T b gambiense is very rare in short-term tourists, but has been reported in immigrants, refugees, and expatriates resident for long periods in rural areas. [23] [24] [25] [26] Because of its long incubation time and chronicity, the disease should be considered even if a patient's last stay in an endemic region occurred many years ago. The number of tourists infected in countries that report the most local patients is low, probably because these countries are rarely visited by travellers (fi gure 1). By contrast, disease due to T b rhodesiense has been reported in short-term tourists travelling to east African game reserves, mainly in Tanzania, [27] [28] [29] [30] but also in Botswana, Rwanda, Kenya, and Malawi.
31

Vector and parasite
Trypanosomes are transmitted by blood-feeding tsetse fl ies of the genus Glossina from one mammalian host to another. Both male and female fl ies are blood-feeders and can thus bring about transmission. About 30 species and subspecies of tsetse fl ies exist, and these are separated into three groups that prefer diff erent habitats 32 and show diff erent abilities to transmit T b gambiense or T b rhodesiense sleeping sickness. The fl ies' biology has one major peculiarity-they are viviparous. The female fl y deposits a fully developed larva, which burrows into the soil, pupates, and emerges as an adult fl y a month later. Newly-hatched fl ies have never been reported to be infected with trypanosomes. The fl y fi rst needs to feed on an infected mammalian host, after which the parasites enter the digestive tract. During the following 3-5 weeks they undergo several diff erentiation steps, including migration to the salivary glands, where they develop into the infective form. The complex process of establishment in the midgut and maturation in the salivary glands depends on many factors, some favouring and others inhibiting its completion (fi gure 3). 33 Completion of the cycle in the fl y is rare in the fi eld, in that only about 0·1% of fl ies carry a mature infection that can be transmitted when the fl y bites another host. Trypanosomes are unicellular organisms (protozoa) that belong to the family Trypanosomatidae and the genus Trypanosoma. 34 The elongated cells are 15-30 μm long and constantly move with the help of a fl agellum. They have the cellular organisation of eukaryotic cells, with one tubular mitochondrion that contains the kinetoplast, which is a condensation of the circular mitochondrial DNA. In the initial phase of infection, trypanosomes are restricted to the lymph and blood systems (fi gure 4). At a later stage they are also seen in brain parenchyma and cerebrospinal fl uid (CSF), 35 but are generally extracellular.
Normal human plasma contains a trypanosome lytic factor. This factor destroys trypanosomes pathogenic for animals, whereas T b gambiense and T b rhodesiense are resistant to it, each by means of a diff erent mechanism. 36 The trypanosome lytic factor has two components, apolipoprotein L1 and haptoglobin-related protein, which are especially active when assembled in one high-density lipoprotein. 37 One reported human infection with T evansi might have been attributable to an absence of apolipoprotein L1 in the patient. Trypanosomes are surrounded by a surface coat composed of a variant surface glycoprotein that protects them from lytic factors in human plasma. 39 When infection occurs, this glycoprotein is recognised by the host's immune system, which starts producing IgM and IgG antibodies. These antibodies neutralise the corresponding trypanosomes, leading to a decrease of parasitaemia. However, a few of the trypanosomes will have changed their surface coats to a new variant surface glycoprotein type that is not aff ected by the circulating antibodies, so that they can continue to proliferate until new antibodies are produced. This sequence continues, and the immune system is not able to eliminate the parasites. About 2000 variant surface glycoprotein genes, including many pseudogenes, are present in the genome of T brucei, 40, 41 whereas T b gambiense probably has fewer. Only one such glycoprotein is expressed at a specifi c time. The switch occurs either by transport of a variant surface glycoprotein gene to one of 20 expression sites situated on diff erent telomeres, or by silencing of an active telomere and activation of a telomere on another chromosome. Because of this high degree of antigenic variation, development of a vaccine is unlikely to be feasible. 42 Domestic and wild animals can also become infected with T b gambiense 43 and T b rhodesiense. Although they do not fall ill, they have an epidemiological role as carriers or reservoir animals from which tsetse fl ies can acquire an infection. 44 For T b rhodesiense, which is a zoonosis that is usually transmitted from animals to man, cattle are an important reservoir, 45, 46 although most wild animals species in game parks can harbour human-pathogenic trypanosomes. For T b gambiense, which is anthroponotic-ie, it mostly depends on human-to-human transmission-man provides the main reservoir. Animals play a less important part, but pigs and some wild animal species have been reported as being a reservoir.
47,43
Clinical features
The disease appears in two stages, the fi rst haemolymphatic stage and the second meningoencephalitic stage, which is characterised by invasion of the CNS. The penetration of trypanosomes through the blood-brain barrier is an active process 48 and occurs at or near intracellular junctions. Disease caused by either of the two parasites leads to coma and death if left untreated. T b gambiense infection is characterised by a chronic progressive course. According to models based on survival analysis, the estimated average duration of such infection is around 3 years, which is evenly divided between the fi rst and second stages. 49 T b rhodesiense disease is usually acute, and death occurs within weeks or months. 50 A trypanosomal chancre (a reaction at the location of the tsetse fl y bite) is rarely seen with T b gambiense, but occurs in 19% of patients infected with T b rhodesiense. The leading signs and symptoms of the fi rst stage are chronic and intermittent fever, headache, pruritus, lymphadenopathy, and, to a lesser extent, hepatosplenomegaly. In the second stage, sleep disturbances and neuropsychiatric disorders dominate the clinical presentation.
Fever is intermittent, with attacks lasting from a day to a week, separated by intervals of a few days to a month or longer, 51 and is rarely seen in the second stage. 52 The febrile episodes correspond to a type 1 infl ammatory reaction associated with activation of macrophage-1 cells and high concentrations of interferon γ, tumour necrosis factor, reactive oxygen intermediates or metabolites, and nitric oxide. This reaction controls parasite invasion and proliferation, but the exacerbated immune response can induce collateral tissue damage. 53 To alleviate parasiteelicited pathological changes the host can mount type 2 immune responses consisting of sequential production of interleukin 10 and interleukin 4 or interleukin 1 that can induce macrophage-2 cells with anti-infl ammatory 1 9 4 4 1 9 4 9 1 9 5 4 1 9 5 9 1 9 6 4 1 9 6 9 1 9 7 4 1 9 7 9 1 9 8 4 1 9 8 9 1 9 9 4 1 9 9 9 2 0 0 4 properties. 53 The mechanism of antigenic variation on the surface of the parasite allows it to persist and to elicit new parasitic waves.
Sleep disorder is a leading symptom of the second stage and is the one that gave the disease its name. Somnographic studies have shown that the disease causes dysregulation of the circadian rhythm of the sleep/wake cycle and a fragmentation of the sleeping pattern rather than the frequently reported inversion of sleep. 54 In severe cases the circadian rhythm of prolactin, renin, growth hormone, and cortisol secretion disappears. 54, 55 The neurological symptoms include tremor, fasciculations, general motor weakness, paralysis of a limb, hemiparesis, akinesia, and abnormal movements such as dyskinesia or chorea-athetosis. There might be Parkinson-like movements due to muscular hypertension, non-specifi c movement disorders, and speech disorders. Abnormal archaic refl exes can also arise. These disorders are rarely seen during the fi rst stage and increase in frequency with the duration of the disease.
52, 56 Psychiatric symptoms such as irritability, psychotic reactions, aggressive behaviour, or inactivity with apathy can dominate the clinical picture. 56 In Europe, infected immigrants have sometimes been wrongly admitted to psychiatric clinics. 57 Cardiac involvement documented by electrocardiogram (ECG) changes is frequently seen in T b gambiense disease, but is rarely of clinical relevance. The most frequent ECG changes are QTc prolongation, repolarisation changes, and low voltage. In T b rhodesiense infection, myopericarditis can be more severe. 58, 59 By contrast with heart problems in Chagas disease, which is caused by another trypanosome, T cruzi, arrhythmias, conduction problems and blocks, and congestive heart failure are rare in African trypanosomiasis. 60, 61 Endocrine disorders of the thyroid and adrenocortical function can take the form of hypofunction or hyperfunction, but rarely demand specifi c treatment. 62 These symptoms are more pronounced in T b rhodesiense disease. 63 The symptomatology of human African trypanosomiasis in travellers is strikingly diff erent from the usual textbook descriptions of African patients, and is similar for both T b gambiense and T b rhodesiense infections, 51 presenting as an acute febrile disease with temperatures up to 40-41°C. 21, 22 In travellers, a chancre at the inoculation site 24 and a trypanosomal rash 22 are more frequently seen, and results of laboratory tests show greater abnormalities than in patients from endemic countries. Severe haematological disorders, impaired kidney function, electrolyte disturbances, high concentrations of C-reactive protein and liver enzymes have been described. 26, 27, 64, 65 A great diversity of clinical pictures can be seen in patients infected by T b gambiense, ranging from acute disease to chronic forms. Asymptomatic carriers are also reported. 66, 67 Whereas an initial genetic characterisation of the infecting T b gambiense in patients in Côte d'Ivoire showed little genetic polymorphism, 66 a PCR analysis done some years later did detect DNA of T brucei sensu lato in healthy carriers. These parasites might represent a distinct and previously unrecognised genetic group of trypanosomes, other than T b gambiense or T b rhodesiense. An infection or coinfection with these T brucei sensu lato could cause a slow and gradual development of morbidity. 68 Additionally, infections of people with trypanosomes thought to be non-pathogenic for man have been described in case reports. 69 Typically, T b rhodesiense disease progresses very rapidly; however, in the southern countries of east Africa, in particular Malawi, a more chronic form has been reported. These two distinct clinical forms have been associated with two genotypes of the SRA gene. Additionally, tumour necrosis factor α concentration was high in early-stage patients in Uganda, whereas in Malawi high concentrations of transforming growth factor β concentrations were seen. 70 However, the apparently 
Diagnosis
The diagnosis and staging of T b gambiense disease rely on laboratory examinations, because the clinical features of the disease are not suffi ciently specifi c. 23,71,72 A threestep approach is used within control programmes and for individual patients: screening, diagnostic confi rmation, and staging.
The card agglutination test for trypanosomiasis/ T b gambiense (CATT), developed in the late 1970s, can be done on serum, capillary blood obtained from a fi nger prick, or blood from impregnated fi lter papers. [73] [74] [75] CATT is a fast and practical serological test that allows hundreds of individuals to be screened daily, and is reported to be 87-98% sensitive and 93-95% specifi c. [76] [77] [78] [79] [80] CATT is the best-adapted and most effi cient screening method, and is widely used for mass population screening in endemic areas (fi gure 5). 81, 82 However, since the test is used in populations where the prevalence of African trypanosomiasis is usually less than 5%, the positive predictive value of a positive CATT remains too low for confi rmation of the disease. There are indications that CATT results might be misleading in specifi c areas as a result of the absence of the LiTat 1·3 antigene. 83 Other highly sensitive serological tests, such as immunofl uorescence or enzyme-linked immuno sorbent assays, are generally used in non-endemic countries to screen individuals with suggestive clinical features or previous exposure. 79, 84 Since serological tests are not 100% sensitive, health professionals are advised to search for trypanosomes in individuals with negative serological tests who have had a recent infection (chancre) or a strong clinical suspicion of African trypanosomiasis.
The microscopic examination of lymph node aspirate and blood, or both, is needed for parasitological confi rmation. The delay between sampling and examination should be kept as short as possible to avoid lysis of trypanosomes. When present, a cervical lymph node is punctured and the fresh aspirate swiftly examined. The sensitivity of lymph node palpation and aspiration varies from 40% to 80% dependent on parasite strain, stage of disease (this test is more sensitive during the fi rst stage), and prevalence of other diseases that cause lymphadenopathy. 85, 86 Because examination of thin or thick blood fi lms has very low sensitivity, concentration methods such as the microhaematocrit centrifugation technique, 87 quantitative buff y coat, 88, 89 and miniature anion-exchange centrifuga tion technique 90 should be used. 82, 91, 92 Serial examinations on consecutive days increase the sensitivity of blood examination techniques. Detection of parasite nucleic acids by PCR might become useful as a more sensitive approach, but existing tests need further standardisation and clinical validation. 71 Some investigators recommend treatment of individuals with high CATT titres (≥1:16), even if parasitological examination is negative, in populations with high disease prevalence (>1%), especially when the most sensitive blood detection methods (quantitative buff y coat or miniature anion-exchange centrifugation technique) cannot be used. 93, 94 This strategy should not be applied when disease prevalence is low. 95 Because treatment diff ers substantially between the fi rst and second stage, diff erentiation between them by examination of the CSF after lumbar puncture is essential. 96 According to WHO recommendations 75 the presence in CSF of more than fi ve white blood cells per μL, trypanosomes, or increased protein content (>370 mg/L) defi nes second-stage disease. The fi ve cells per μL threshold is most widely used, but some controversy exists about the group of patients with six to 
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Whereas the microscopic fi nding of trypanosomes is diagnostic of second-stage disease, the clinical signifi cance of a positive PCR on a CSF sample is controversial. 101, 102 Total protein measurement in the CSF is no longer recommended. By contrast, increased IgM concentrations in CSF, caused by synthesis within the spinal cord, are an early and specifi c marker of CNS invasion. [103] [104] [105] A fi eld-designed latex agglutination test for IgM in CSF has shown promising results, but needs further validation. 106 Antibodies against neurofi laments, galactocerebrosides, neurofi laments, and glial fi brillary acidic proteins are also promising CSF markers of second-stage disease.
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The diagnostic approach for T b rhodesiense disease diff ers from that for T b gambiense in several ways. First, there is no serological screening test for T b rhodesiense. Rather, the identifi cation of suspected cases relies on the non-specifi c clinical presentation and history of exposure. Second, parasitological confi rmation is easier for T b rhodesiense, because the density of blood circulating parasites is higher than for T b gambiense. A thin or thick blood smear is usually suffi cient to confi rm diagnosis. And third, biological indices such as haemoglobin and platelet counts, and coagulation tests are more frequently or substantially changed in African trypanosomiasis caused by T b rhodesiense than in that caused by T b gambiense, but these fi ndings remain non-specifi c.
Research and development of methods for diagnosis and staging of disease have been revitalised, notably through an initiative launched in 2006 by WHO and the Foundation for Innovative New Diagnostics (FIND). 110 Present research eff orts focus on several areas: (i) recombinant or native trypanosome antigens that could be used to develop an improved serological test; (ii) methods to detect parasite antigens in blood or CSF; (iii) proteomic fi ngerprinting; (iv) low-tech PCR methods such as loop-mediated isothermal amplifi cation or oligochromatography; and (v) new blood or CSF markers of second-stage disease.
111-115
Treatment Pentamidine
Few drugs are available to treat human African trypanosomiasis and selection is based mainly on the disease stage and causative pathogen (table) . At present, all drugs are donated to WHO by the producers. 116, 117 Pentamidine is the drug of choice for treatment of fi rststage disease caused by T b gambiense. It is given intramuscularly for a week , unless it can be given as an intravenous infusion in saline over 2 h. There is pharmacokinetic evidence that three injections might be equally eff ective, 118, 119 and a comparative clinical trial is in progress to test this strategy (trial registration ISRCTN55042030). By contrast, the use of pentamidine in intermediate-stage disease (ie, up to ten or 20 white blood cells per μL in CSF) 120 has produced equivocal outcomes 97 ,99,100 and should not be generally recommended. Attention has been drawn to an unintended modifi cation of the dose calculation from the base to the salt, 121 but this change should lead to a clarifi cation of the label rather than a change in practice, because pentamidine at the currently used dose is still very eff ective. Pentamidine is generally well tolerated. When given by intramuscular injection, site pain and transient swelling, abdominal pain and gastrointestinal problems, and hypoglycaemia (5-40%) are the most frequently reported adverse events. 122 Other important adverse drug reactions such as leucopenia, thrombocytopenia, hyperkalaemia, and QT-prolongation, which are seen in treatment of other diseases (eg, Pneumocystis jirovecii infection 123 ), are rarely reported, probably because of the scarcity of adequate methods for patient monitoring.
Suramin
Suramin is used for fi rst-stage T b rhodesiense disease, but is generally avoided against T b gambiense disease in western and central Africa because where Onchocerca spp are also present, its high activity against these parasites can expose patients to the risk of severe allergic reactions. The recommended dose regimens for suramin are complex and last up to 30 days. 124 The compound deteriorates rapidly in air and should be injected immediately after dilution in distilled water. 125 Adverse drug reactions are frequent but usually mild and reversible, including nephrotoxicity, peripheral neuropathy, and bone marrow toxicity with agranulocytosis and thrombocytopenia. Rare acute and late hypersensitivity reactions can occur, 32 of which the acute reaction is the reason for the low test dose generally applied before treatment initiation.
Melarsoprol
The organoarsenic compound melarsoprol remains the most widely used drug for treatment of second-stage disease caused by T b gambiense in resource-poor countries where the new drug efl ornithine is not available or aff ordable, and it is the only choice for second-stage T b rhodesiense. For T b gambiense an abridged treatment schedule of ten injections on consecutive days was recommended by the International Scientifi c Council for Trypanosomiasis Research and Control. 126 For treatment of T b rhodesiense, various lengthy and complex treatment schedules are still used (table); work on the abridged schedule is continuing. Adverse reactions to melarsoprol are frequent and can be severe or even life-threatening. The most important reaction is an encephalopathic syndrome, which occurs with very variable frequency in an average 4·7% of T b gambiense and 8·0% of T b rhodesiense patients, with a case fatality rate of 44% and 57%, respectively. 127 For the management of encephalopathic syndrome, dexamethasone and diazepam are recommended. 122 Careful monitoring of the patient during treatment is crucial and although not indicative, the appearance of fever or fever combined with headaches can be regarded as warning signs. 128 Skin reactions such as pruritus and maculopapular eruptions are fairly common, but severe complications such as bullous eruptions occur in less than 1% of cases. 78, 126 Peripheral motor (palsy) or sensorial (paraesthesia) neuropathies have been reported. A good injection technique is mandatory to mitigate the irritating and painful eff ects of the injections, often leading to thrombophlebitis. In several foci, treatment failures have reached 30% of those treated. These failures suggest the emergence of resistance to melarsoprol, in which a P2 adenosine transporter might be implicated. 129 So far, however, diffi culties in retrieval of T b gambiense isolates from patients have hampered demonstration of parasite resistance.
Efl ornithine
Efl ornithine is the only new molecule for the treatment of human African trypanosomiasis that has been registered in the past 50 years. Several studies comparing melarsoprol with efl ornithine have shown a clearly reduced mortality with efl ornithine, which is therefore recommended as the fi rst-line treatment for second-stage T b gambiense disease, [130] [131] [132] but the use of efl ornithine against T b rhodesiense is not advised, because this organism is innately less susceptible to the drug than is T b gambiense. 133 Treatment of T b gambiense infection with efl ornithine lasts for 2 weeks, and because of the short half-life of the drug, four short infusions per day are necessary (see table) . This regimen hampers the replacement of melarsoprol by efl ornithine in rural public treatment facilities. The provision of kits by WHO, including all the necessary ancillary materials, could mitigate some of the diffi culties. 134 Attempts were made to reduce the diffi culty of drug administration by use of an oral formulation, but were abandoned after a pharmacokinetic trial gave discouraging results. 135, 136 Adverse drug reactions are similar to those of other cytostatic drugs, and include bone marrow toxicity leading to anaemia, leucopenia, and thrombocytopenia (25-50%), gastrointestinal symptoms (10-39%), and convulsions (7%). 137 Superimposed bacterial infection at the catheter site can lead to life-threatening sepsis, but this event can be prevented by adequate nursing care.
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Prevention and control
There is no vaccine against trypanosome infection, and chemoprophylaxis is not recommended because of the toxicity of the drugs and the low risk of infection. The only preventive measure is reduction of tsetse fl y bites. The fl ies are attracted to dark colours, in particular blue and black, and to the motion of vehicles. They can bite through thin clothes, and insect repellents provide only part protection. Travellers can take some preventive measures, such as avoidance of areas where tsetse fl ies are known to be present, travelling in cars with screened or closed windows in endemic foci, use of insect repellents, and clothes of wrist and ankle length. After a person is bitten by a tsetse fl y, they should be monitored, although the risk of an infection is low. If a chancre, fever, or other symptom develops, an aspirate of the chancre, the blood, and possibly a lymph node aspirate should be examined for the presence of trypanosomes. In T b gambiense areas the CATT could be used.
The most important control measure for T b gambiense disease is active case-finding followed by treatment of the identified patients. Infected people can remain asymptomatic for long periods before they develop signs of sleeping sickness, but they always act as a reservoir. Although animals have a less important role as reservoirs for T b gambiense, for T b rhodesiense, domestic (cattle, dogs) and wild animals (mainly antelopes) provide a vast reservoir that should be taken into consideration for control. 139, 140 Vector control by use of tsetse fl y traps or screens, in combination with odours that attract the fl ies, or insecticides, helps to reduce the fl y density. Chemoprophylaxis is no longer in use because of the poor risk-benefit ratio caused by the adverse eff ects of the drugs.
The biological cycle of human African trypanosomiasis is very fragile because transmission through the tsetse fl y is complex and slow. As a result, even in countries where the disease is endemic, less than 0·1% of fl ies carry mature parasites. The prevalence in man is also low apart from in epidemic foci. If the density of fl ies and infected individuals is lower than crucial limits, transmission can break down. This situation is more likely to occur for disease due to T b gambiense (small animal reservoir) than for that caused by T b rhodesiense (substantial reservoir of domestic and wild animals).
In 2002, the WHO HAT [human African trypanosomiasis] control and surveillance programme established a worldwide alliance to eliminate sleeping sickness. 141 Even earlier, the Pan-African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC) was founded as a taskforce uniting African countries aff ected by African trypanosomiasis to fi ght and eventually eliminate the disease. 142 The main strategy of PATTEC is elimination of the tsetse fl y in isolated foci through an integrated approach that combines insecticide spraying, traps, and the sterile insect technique. The use of sterile male fl ies resulted in the eradication of tsetse fl ies on Unguja Island in Zanzibar, 143 but the enormous cost of this method is likely to restrict its use, especially in areas where several vector species cause transmission. Many tsetse control experts do not share the PATTEC view, but rather advocate the use of simple technologies such as traps in combination with insecticides and attractants. 144 For the region endemic for T b rhodesiense a restricted application of insecticides to cattle (especially belly and legs) represents a cost-eff ective method of tsetse control. 145 Elimination of African trypanosomiasis is thought to be feasible by WHO. 15 However, a prerequisite is to have new reliable methods for diagnosis and staging, and new, safe, eff ective, and easy-to-apply drugs for both stages of disease. Furthermore, participation of the national programmes of all aff ected African countries is paramount. To guarantee sustainability, additional partners are needed-international organisations, nongovernmental organisations, and philanthropic organisations-to maintain the eff ort over decades. If this strategy can be realised, eff orts to eliminate the disease will have a real chance of success.
Research priorities
Recent eff orts have focused on fi nding optimum therapeutic regimens and on development of combination therapy with drugs already registered or those used to treat related diseases. For example, the oral drug nifurtimox, registered for treatment of Chagas disease, was considered for compassionate treatment, in combination with other trypanocidal drugs, of patients who did not respond to melarsoprol. 146 Gastrointestinal disturbances with nausea, abdominal pains, and vomiting are very frequent, and neurological adverse reactions with general convulsions, tremor, or agitation can occur. 32 The frequency of adverse reactions increases with treatment duration and all are rapidly reversible after discontinuation of the drug. 147 Various combinations of efl ornithine, melarsoprol, and nifurtimox have been tested and in all trials the effi cacy was better than with monotherapy. However, combinations containing melarsoprol resulted in very high rates of severe adverse drug reactions. 146, 148 As a result of those investigations, a multicountry trial of nifurtimox-efl ornithine combination therapy was undertaken to compare the standard efl ornithine therapy with an abridged regimen consisting of 200 mg/kg of efl ornithine given as a short intravenous infusion every 12 h for 7 days, combined with nifurtimox 5 mg/kg given orally every 8 h for 10 days. This regimen reduces the number of infusions from 56 to 14 and the treatment duration from 14 to 10 days. 149, 150 Some data reported so far suggest the combination is rather well tolerated and has a good intermediary eff ectiveness. 150 The development of new medicines against human African trypanosomiasis underwent a serious setback when the new oral fi rst-stage diamidine drug, pafuramidine maleate (DB289), failed almost at the end of the development programme because of nephrotoxicity. 151, 152 However, a back-up programme identifi ed new diamidines that could cure a CNS mouse model of infection (JE Hall and R Brun, unpublished results). Currently, no molecules are at the stage of clinical development for treatment of African trypanosomiasis. However, one molecule, the nitroimidazole fexinidazole, has been advanced from discovery to the preclinical stage, and profi ling is in progress. If this process is successful, the fi rst phase 1 studies in man should begin in 2009. 153, 154 Contributors RB designed the article and drafted the sections on parasite and vector, and control. JB and FC drafted the clinical and diagnostic sections and contributed illustrations to the epidemiology. CB drafted the section on treatment and was responsible for an in-depth review of published work. All authors were involved in the fi nalisation of the manuscript and approved the fi nal version.
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